The mTOR Signalling Pathway in Human Cancer

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590

Repertoires of Autophagy in the Pathogenesis of Ocular Diseases

Li, Y., Jiang, Q. L., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,351

Autophagy in the Pathogenesis of Disease

Levine, B., & Kroemer, G. (2008) · Cell · doi:10.1016/j.cell.2007.12.018 · Cited by 7,069

Autophagy fights disease through cellular self-digestion

Mizushima, N., Levine, B., Cuervo, A. M., & Klionsky, D. J. (2008) · Nature · doi:10.1038/nature06639 · Cited by 6,452

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216

The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

Vivanco, I., & Sawyers, C. L. (2002) · Nature reviews. Cancer · doi:10.1038/nrc839 · Cited by 6,155

TOR signaling in growth and metabolism

Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787

PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer

Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785

Autophagy and Viruses: Adversaries or Allies?

Dong, X., & Levine, B. (2013) · Journal of Innate Immunity · doi:10.1159/000346388 · Cited by 4,444

Upstream and downstream of mTOR

Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181

TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival

Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914

AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint

Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849

Rapamycin fed late in life extends lifespan in genetically heterogeneous mice

Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766

Development by Self-Digestion

Levine, B., & Klionsky, D. J. (2004) · Developmental Cell · doi:10.1016/s1534-5807(04)00099-1 · Cited by 3,728

Anorexigenic and Orexigenic Hormone Modulation of Mammalian Target of Rapamycin Complex 1 Activity and the Regulation of Hypothalamic Agouti-Related Protein mRNA Expression

Watterson, K. R., Bestow, D., Gallagher, J. R., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2012) · Neurosignals · doi:10.1159/000334144 · Cited by 3,395

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083

mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery

Kim, D., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument‐Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 3,051

Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα

Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 2,874

Defining the role of mTOR in cancer

Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788

Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton

Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561

Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN

Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551

Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB

Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365

Caloric Restriction Delays Disease Onset and Mortality in Rhesus Monkeys

Colman, R. J., Anderson, R. M., Johnson, S. C., Kastman, E. K., Kosmatka, K. J., Beasley, T. M., Allison, D. B., Cruzen, C., Simmons, H. A., Kemnitz, J. W., et al. (2009) · Science · doi:10.1126/science.1173635 · Cited by 2,277

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,097

Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome

Liaw, D., Marsh, D. J., Li, J., Dahia, P. L. M., Wang, S. I., Zheng, Z., Bose, S., Call, K. M., Tsou, H. C., Peacoke, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-64 · Cited by 2,067

A mammalian protein targeted by G1-arresting rapamycin–receptor complex

Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053

Ras, PI(3)K and mTOR signalling controls tumour cell growth

Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019

Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast

Heitman, J., Movva, N. R., & Hall, M. N. (1991) · Science · doi:10.1126/science.1715094 · Cited by 2,010

Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling

Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes & Development · doi:10.1101/gad.1110003 · Cited by 1,911

Two TOR Complexes, Only One of which Is Rapamycin Sensitive, Have Distinct Roles in Cell Growth Control

Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886

Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action

Hara, K., Maruki, Y., Long, X., Yoshino, K.-I., Oshiro, N., Sujuti, H., Tokunaga, C., Avruch, J., & Yonezawa, K. (2002) · Cell · doi:10.1016/s0092-8674(02)00833-4 · Cited by 1,810

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.

Vézina, C., KUDELSKI, A., & Sehgal, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,691

Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677

Termination of autophagy and reformation of lysosomes regulated by mTOR

Yu, L., McPhee, C. K., Zheng, L., Mardones, G. A., Rong, Y., Peng, J., Mi, N., Zhao, Y., Liu, Z., Wan, F., et al. (2010) · Nature · doi:10.1038/nature09076 · Cited by 1,544

RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs

Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., & Snyder, S. H. (1994) · Cell · doi:10.1016/0092-8674(94)90570-3 · Cited by 1,509

Ablation in Mice of the mTORC Components raptor, rictor, or mLST8 Reveals that mTORC2 Is Required for Signaling to Akt-FOXO and PKCα, but Not S6K1

Guertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J., & Sabatini, D. M. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.10.007 · Cited by 1,467

SIN1/MIP1 Maintains rictor-mTOR Complex Integrity and Regulates Akt Phosphorylation and Substrate Specificity

Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J., & Su, B. (2006) · Cell · doi:10.1016/j.cell.2006.08.033 · Cited by 1,407

Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex

Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381

Phosphorylation and Functional Inactivation of TSC2 by Erk

Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., & Pandolfi, P. P. (2005) · Cell · doi:10.1016/j.cell.2005.02.031 · Cited by 1,268

Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function

Pause, A., Belsham, G. J., Gingras, A., Donzé, O., Lin, T.-A., Lawrence, J. C., & Sonenberg, N. (1994) · Nature · doi:10.1038/371762a0 · Cited by 1,242

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A., & Sabatini, D. M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.03.003 · Cited by 1,236

Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40

Haar, E. V., Lee, S.-I., Bandhakavi, S., Griffin, T. J., & Kim, D. (2007) · Nature Cell Biology · doi:10.1038/ncb1547 · Cited by 1,227

Dual Role of Phosphatidylinositol-3,4,5-trisphosphate in the Activation of Protein Kinase B

Stokoe, D., Stephens, L. R., Copeland, T., Gaffney, P. R. J., Reese, C. B., Painter, G. F., Holmes, A. B., McCormick, F. P., & Hawkins, P. T. (1997) · Science · doi:10.1126/science.277.5325.567 · Cited by 1,216

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival

Peterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202

Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin

Hudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., & Abraham, R. T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.20.7004-7014.2002 · Cited by 1,186

The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins

Harrington, L. S., Findlay, G. M., Gray, A., Толкачева, Т. А., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403069 · Cited by 1,123

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,108

The LKB1 tumor suppressor negatively regulates mTOR signaling

Shaw, R. J., Bardeesy, N. M., Manning, B. D., Lopez, L. V., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,107

Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E

Fingar, D. C., Salama, S., Tsou, C., Harlow, E., & Blenis, J. (2002) · Genes & Development · doi:10.1101/gad.995802 · Cited by 1,093

An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.

Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054

Current development of mTOR inhibitors as anticancer agents

Faivre, S. J., Kroemer, G., & Raymond, É. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2062 · Cited by 1,012

Rheb Binds and Regulates the mTOR Kinase

Long, X., Lin, Y., Ortiz-Vega, S., Yonezawa, K., & Avruch, J. (2005) · Current Biology · doi:10.1016/j.cub.2005.02.053 · Cited by 1,005

GβL, a Positive Regulator of the Rapamycin-Sensitive Pathway Required for the Nutrient-Sensitive Interaction between Raptor and mTOR

Kim, D., Sarbassov, D. D., Ali, S. M., Latek, R. R., Guntur, K., Erdjument‐Bromage, H., Tempst, P., & Sabatini, D. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00114-x · Cited by 992

Dysregulation of the TSC-mTOR pathway in human disease

Inoki, K., Corradetti, M. N., & Guan, K. (2004) · Nature Genetics · doi:10.1038/ng1494 · Cited by 980

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR

Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B. L., THOMAS, G. V., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 971

The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway

Sansal, I., & Sellers, W. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.141 · Cited by 933

Mutation of the PIK3CA Gene in Ovarian and Breast Cancer

Campbell, I., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., Cristiano, B. E., Pearson, R. B., & Phillips, W. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2933 · Cited by 917

lnterleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin

Nourse, J. L., Firpo, E. J., Flanagan, W. M., Coats, S., Polyák, K., Lee, M., Massagué, J., Crabtree, G. R., & Roberts, J. M. (1994) · Nature · doi:10.1038/372570a0 · Cited by 889

Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells

Sabers, C. J., Martin, M. M., Brunn, G. J., Williams, J. M., Dumont, F. J., Wiederrecht, G., & Abraham, R. T. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.2.815 · Cited by 887

Hierarchical phosphorylation of the translation inhibitor 4E-BP1

Gingras, A.-C., Raught, B., Gygi, S. P., Niedzwiecka, A., Miron, M., Burley, S. K., Polakiewicz, R. D., Wyslouch-Cieszynska, A., Aebersold, R., & Sonenberg, N. (2001) · Genes & Development · doi:10.1101/gad.912401 · Cited by 883

Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression

Kunz, J., Henríquez, R., Schneider, U., Deuter‐Reinhard, M., Movva, N. R., & Hall, M. N. (1993) · Cell · doi:10.1016/0092-8674(93)90144-f · Cited by 838

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

Chresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1751 · Cited by 812

Inappropriate Activation of the TSC/Rheb/mTOR/S6K Cassette Induces IRS1/2 Depletion, Insulin Resistance, and Cell Survival Deficiencies

Shah, O. J., Wang, Z., & Hunter, T. R. (2004) · Current Biology · doi:10.1016/j.cub.2004.08.026 · Cited by 800

Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase

Nobukuni, T., Joaquin, M., Roccio, M., Dann, S. G., Kim, S. Y., Gulati, P., Byfield, M. P., Backer, J., Natt, F., Bos, J. L., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506925102 · Cited by 775

eIF-4E expression and its role in malignancies and metastases

Benedetti, A. D., & Graff, J. R. (2004) · Oncogene · doi:10.1038/sj.onc.1207545 · Cited by 751

mSin1 Is Necessary for Akt/PKB Phosphorylation, and Its Isoforms Define Three Distinct mTORC2s

Frías, M. A., Thoreen, C. C., Jaffe, J. D., Schroder, W. A., Sculley, T. B., Carr, S. A., & Sabatini, D. M. (2006) · Current Biology · doi:10.1016/j.cub.2006.08.001 · Cited by 690

Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1

Um, S. H., D'Alessio, D., & Thomas, G. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.05.003 · Cited by 690

The Mammalian Target of Rapamycin (mTOR) Partner, Raptor, Binds the mTOR Substrates p70 S6 Kinase and 4E-BP1 through Their TOR Signaling (TOS) Motif

Nojima, H., Tokunaga, C., Eguchi, S., Oshiro, N., Sujuti, H., Yoshino, K., Hara, K., Tanaka, N., Avruch, J., & Yonezawa, K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200665200 · Cited by 678

The mRNA 5′ cap-binding protein eIF4E and control of cell growth

Sonenberg, N., & Gingras, A. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80150-6 · Cited by 673

mTOR·RICTOR Is the Ser473 Kinase for Akt/Protein Kinase B in 3T3-L1 Adipocytes

Hresko, R. C., & Mueckler, M. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508361200 · Cited by 642

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Heß, G., Herbrecht, R., Romaguera, J. E., Verhoef, G. E. G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F. C., Strahs, A. L., Berkenblit, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7977 · Cited by 641

Human eukaryotic translation initiation factor 4G (eIF4G) recruits Mnk1 to phosphorylate eIF4E

Pyronnet, S., Imataka, H., Gingras, A., Fukunaga, R., Hunter, T., & Sonenberg, N. (1999) · The EMBO Journal · doi:10.1093/emboj/18.1.270 · Cited by 639

IKKβ Suppression of TSC1 Links Inflammation and Tumor Angiogenesis via the mTOR Pathway

Lee, D., Kuo, H.-P., Chen, C., Hsu, J.-M., Chou, C., Wei, Y., Sun, H., Li, L., Ping, B., Huang, W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.05.058 · Cited by 639

Signaling Pathways and Molecular Mechanisms through which Branched-Chain Amino Acids Mediate Translational Control of Protein Synthesis

Kimball, S. R., & Jefferson, L. S. (2006) · Journal of Nutrition · doi:10.1093/jn/136.1.227s · Cited by 637

mTOR-targeted therapy of cancer with rapamycin derivatives

Vignot, S., Faivre, S. J., de Aguirre, & Raymond, É. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi113 · Cited by 613

Hypoxia-induced energy stress regulates mRNA translation and cell growth

Liu, L., Cash, T. P., Jones, R. G., Keith, B., Thompson, C. B., & Simon, M. C. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.010 · Cited by 607

The NF1 tumor suppressor critically regulates TSC2 and mTOR

Johannessen, C. M., Reczek, E. E., James, M. F., Brems, H., Legius, E., & Cichowski, K. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503224102 · Cited by 605

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

Thomas, G. V., Tran, C., Mellinghoff, I. K., Welsbie, D. S., Chan, E., Fueger, B., Czernin, J., & Sawyers, C. L. (2006) · Nature Medicine · doi:10.1038/nm1337 · Cited by 604

Deregulated Akt3 Activity Promotes Development of Malignant Melanoma

Stahl, J. M., Sharma, A. K., Cheung, M., Zimmerman, M., Cheng, J. Q., Bosenberg, M., KESTER, M. A., Sandirasegarane, L., & Robertson, G. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1399 · Cited by 595

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

Cloughesy, T. F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., Hsueh, T., Chen, Y., Wang, W., Youngkin, D., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050008 · Cited by 593

The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis

Ruggero, D., Montanaro, L., Ma, L., Xu, W. G., Londei, P., Cordon‐Cardo, C., & Pandolfi, P. P. (2004) · Nature Medicine · doi:10.1038/nm1042 · Cited by 592

The TOR signaling cascade regulates gene expression in response to nutrientsPreprint

Cardenas, M. E., Cutler, N. S., Lorenz, M. C., Como, C. J. D., & Heitman, J. (1999) · Genes & Development · doi:10.1101/gad.13.24.3271 · Cited by 580

Identification of a Novel Hypoxia-Inducible Factor 1-Responsive Gene, RTP801 , Involved in Apoptosis

Shoshani, T., Faerman, A., Mett, I., Zelin, E., Tenne, T., Gorodin, S., Moshel, Y., Elbaz, S., Budanov, A., Chajut, A., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.7.2283-2293.2002 · Cited by 546

mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availabilityPreprint

Mayer, C., Zhao, J., Yuan, X., & Grummt, I. (2004) · Genes & Development · doi:10.1101/gad.285504 · Cited by 544

Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises

Yap, T. A., Garrett, M. D., Walton, M. I., Raynaud, F., de Bono, J. S., & Workman, P. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.08.004 · Cited by 543

Regulation of ribosome biogenesis by the rapamycin-sensitive TOR-signaling pathway in Saccharomyces cerevisiae.

Powers, T., & Walter, P. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.4.987 · Cited by 540

hVps34 Is a Nutrient-regulated Lipid Kinase Required for Activation of p70 S6 Kinase

Byfield, M. P., Murray, J. T., & Backer, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507201200 · Cited by 539

Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity

Hahn-Windgassen, A., Nogueira, V., Chen, C.-C., Skeen, J. E., Sonenberg, N., & Hay, N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502876200 · Cited by 539

TOS Motif-Mediated Raptor Binding Regulates 4E-BP1 Multisite Phosphorylation and Function

Schalm, S. S., Fingar, D. C., Sabatini, D. M., & Blenis, J. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00329-4 · Cited by 528

Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins

Hardwick, J. S., Kuruvilla, F. G., Tong, J. K., Shamji, A. F., & Schreiber, S. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14866 · Cited by 523

PIK-Related Kinases: DNA Repair, Recombination, and Cell Cycle Checkpoints

Keith, C. T., & Schreiber, S. L. (1995) · Science · doi:10.1126/science.270.5233.50 · Cited by 521

The TSC1-TSC2 Complex Is Required for Proper Activation of mTOR Complex 2

Huang, J., Dibble, C. C., Matsuzaki, M., & Manning, B. D. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00289-08 · Cited by 520

Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein.

Peterson, R., Desai, B. N., Hardwick, J. S., & Schreiber, S. (1999) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.96.8.4438 · Cited by 496

The expanding TOR signaling network

Martin, D. E., & Hall, M. N. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.02.008 · Cited by 496

Identification of a Conserved Motif Required for mTOR Signaling

Schalm, S. S., & Blenis, J. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00762-5 · Cited by 490

mTOR-Dependent Regulation of Ribosomal Gene Transcription Requires S6K1 and Is Mediated by Phosphorylation of the Carboxy-Terminal Activation Domain of the Nucleolar Transcription Factor UBF†

Hannan, K. M., Brandenburger, Y., Jenkins, A., Sharkey, K., Cavanaugh, A. H., Rothblum, L. I., Moss, T., Poortinga, G., McArthur, G. A., Pearson, R. B., et al. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.23.8862-8877.2003 · Cited by 489

Rheb fills a GAP between TSC and TOR

Manning, B. (2003) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.09.003 · Cited by 483

PTEN signaling pathways in melanoma

Wu, H., Goel, V., & Haluska, F. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206451 · Cited by 478

Regulation of Peroxisome Proliferator–Activated Receptor-γ Activity by Mammalian Target of Rapamycin and Amino Acids in Adipogenesis

Kim, J. E., & Chen, J. (2004) · Diabetes · doi:10.2337/diabetes.53.11.2748 · Cited by 478

Genetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma

Tsao, H., Yang, G., Goel, V., Wu, H., & Haluska, F. G. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2004.22243.x · Cited by 476

Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR

Yokogami, K., Wakisaka, S., Avruch, J., & Reeves, S. A. (2000) · Current Biology · doi:10.1016/s0960-9822(99)00268-7 · Cited by 474

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

García‐Martínez, J. M., Moran, J., Clarke, R. G., Gray, A., Cosulich, S. C., Chresta, C. M., & Alessi, D. R. (2009) · Biochemical Journal · doi:10.1042/bj20090489 · Cited by 473

mTOR and cancer therapy

Easton, J. B., & Houghton, P. J. (2006) · Oncogene · doi:10.1038/sj.onc.1209886 · Cited by 468

Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance

Tremblay, F., Brûlé, S., Hee Um, S., Li, Y., Masuda, K., Roden, M., Sun, X. J., Krebs, M., Polakiewicz, R. D., Thomas, G., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706517104 · Cited by 465

Identification of Protor as a novel Rictor-binding component of mTOR complex-2

Pearce, L. R., Huang, X., Boudeau, J., Pawłowski, R., Wullschleger, S., Deák, M., Ibrahim, A. F. M., Gourlay, R., Magnuson, M. A., & Alessi, D. R. (2007) · Biochemical Journal · doi:10.1042/bj20070540 · Cited by 462

Rapamycin and mTOR kinase inhibitors

Ballou, L. M., & Lin, R. Z. (2008) · Journal of Chemical Biology · doi:10.1007/s12154-008-0003-5 · Cited by 458

Regulation of mTOR and Cell Growth in Response to Energy Stress by REDD1

Sofer, A., Lei, K., Johannessen, C. M., & Ellisen, L. W. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.14.5834-5845.2005 · Cited by 449

Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin

Phung, T. L., Ziv, K., Dabydeen, D. A., Eyiah-Mensah, G., Riveros, M., Perruzzi, C. A., Sun, J., Monahan-Earley, R. A., Shiojima, I., Nagy, J. A., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.07.003 · Cited by 447

Targeting mTOR signaling for cancer therapy

Huang, S. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(03)00071-7 · Cited by 441

Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycinPreprint

Oldham, S., Montagne, J., Radimerski, T., Thomas, G., & Hafen, E. (2000) · Genes & Development · doi:10.1101/gad.845700 · Cited by 430

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.

Yu, K., Toral‐Barza, L., Discafani, C. M., Zhang, W. G., Skotnicki, J. S., Frost, P., & Gibbons, J. J. (2001) · Endocrine Related Cancer · doi:10.1677/erc.0.0080249 · Cited by 420

The Immunosuppressant Rapamycin Mimics a Starvation-Like Signal Distinct from Amino Acid and Glucose Deprivation

Peng, T., Golub, T. R., & Sabatini, D. M. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.15.5575-5584.2002 · Cited by 404

A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1

Özeş, O. N., Akça, H., Mayo, L. D., Gustin, J. A., Maehama, T., Dixon, J. E., & Donner, D. B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051042298 · Cited by 386

Identification of a Proline-rich Akt Substrate as a 14-3-3 Binding Partner

Kovacina, K. S., Park, G. Y., Bae, S. S., Guzzetta, A. W., Schaefer, E., Birnbaum, M. J., & Roth, R. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210837200 · Cited by 374

HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway

Zhou, B. P., Hu, M. C. ‐., Miller, S. A., Yu, Z., Xia, W., Lin, S., & Hung, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.11.8027 · Cited by 371

Mechanism of action of the immunosuppressant rapamycin

Dumont, F. J., & Su, Q. (1995) · Life Sciences · doi:10.1016/0024-3205(95)02233-3 · Cited by 356

Activity of rapamycin (AY-22,989) against transplanted tumors.

Eng, C. P., Sehgal, S. N., & Vézina, C. (1984) · The Journal of Antibiotics · doi:10.7164/antibiotics.37.1231 · Cited by 354

Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases

Raynaud, F. I., Eccles, S. A., Clarke, P. A., Hayes, A., Nutley, B. P., Alix, S., Henley, A. T., Di-Stefano, F., Ahmad, Z., Guillard, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4615 · Cited by 354

Prognostic relevance of the mTOR pathway in renal cell carcinoma

Pantuck, A. J., Seligson, D. B., Klatte, T., Yu, H., Leppert, J. T., Moore, L., O’Toole, T. E., Gibbons, J., Belldegrun, A. S., & Figlin, R. A. (2007) · Cancer · doi:10.1002/cncr.22677 · Cited by 351

M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase

Glantschnig, H., Fisher, J. E., Wesolowski, G., Rodan, G. A., & Reszka, A. A. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401285 · Cited by 350

Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

Oza, A. M., Elit, L. M., Tsao, M., Kamel‐Reid, S., Biagi, J. J., Provencher, D. M., Gotlieb, W. H., Hoskins, P. J., Ghatage, P., Tonkin, K. S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1578 · Cited by 344

Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

Yu, K., Toral‐Barza, L., Shi, C., Zhang, W., Lucas, J., Shor, B., Kim, J., Verheijen, J. C., Curran, K. J., Malwitz, D. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0299 · Cited by 344

Tuberous Sclerosis: from Tubers to mTOR

Kwiatkowski, D. J. (2003) · Annals of Human Genetics · doi:10.1046/j.1469-1809.2003.00012.x · Cited by 340

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML

Zeng, Z., Sarbassov, D. D., Samudio, I. J., Yee, K. W. L., Munsell, M. F., Jackson, C. E., Giles, F. J., Sabatini, D. M., Andreeff, M., & Konopleva, M. Y. (2006) · Blood · doi:10.1182/blood-2006-06-030833 · Cited by 339

Prognostic Significance of Activated Akt Expression in Melanoma: A Clinicopathologic Study of 292 Cases

Dai, D. L., Martinka, M., & Li, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.168 · Cited by 328

mTOR, translational control and human disease

Tee, A. R., & Blenis, J. (2005) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2004.11.005 · Cited by 325

Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer Cells

Mondesire, W. H., Jian, W., Zhang, H., Ensor, J., Hung, M., Mills, G. B., & Meric‐Bernstam, F. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0361 · Cited by 319

Antiangiogenic Potential of the Mammalian Target of Rapamycin Inhibitor Temsirolimus

Bufalo, D. D., Ciuffreda, L., Trisciuoglio, D., Desideri, M., Cognetti, F., Zupi, G., & Milella, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2825 · Cited by 318

Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis.

Bärlund, M., Forozan, F., Kononen, J., Bubendorf, L., Chen, Y.-D., Bittner, M. L., Torhorst, J., Haas, P., Bucher, C., Sauter, G., et al. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1252 · Cited by 305

Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?

Repasky, G. A., Chenette, E. J., & Der, C. J. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.09.014 · Cited by 299

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

Witzig, T. E., Reeder, C. B., LaPlant, B. R., Gupta, M., Johnston, P. B., Micallef, I. N., Porrata, L. F., Ansell, S. M., Colgan, J. P., Jacobsen, E. D., et al. (2010) · Leukemia · doi:10.1038/leu.2010.226 · Cited by 297

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer

Wolpin, B. M., Hezel, A. F., Abrams, T., Blaszkowsky, L. S., Meyerhardt, J. A., Chan, J. A., Enzinger, P. C., Allen, B., Clark, J. W., Ryan, D. P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9514 · Cited by 297

Determinants of Rapamycin Sensitivity in Breast Cancer Cells

Noh, W.-C., Mondesire, W. H., Peng, J., Jian, W., Zhang, H., Dong, J., Mills, G. B., Hung, M., & Meric‐Bernstam, F. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0043 · Cited by 282

4E-Binding Protein 1: A Key Molecular “Funnel Factor” in Human Cancer with Clinical Implications

Armengol, G., Rojo, F., Castellví, J., Iglesias, C., Cuatrecasas, M., Pons, B., Baselga, J. M., & y Cajal, S. R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0881 · Cited by 279

Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.

Grünwald, V., deGraffenried, L. A., Russel, D., Friedrichs, W. E., Ray, R. B., & Hidalgo, M. M. (2002) · PubMed · Cited by 274

The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma

Friedegund, M. (2005) · Frontiers in bioscience · doi:10.2741/1755 · Cited by 271

A novel AKT3 mutation in melanoma tumours and cell lines

Davies, M. A., Stemke‐Hale, K., Tellez, C. S., Calderone, T. L., Deng, W., Prieto, V. G., Lazar, A. J., Gershenwald, J. E., & Mills, G. B. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604637 · Cited by 268

Regulation of translation elongation factor‐2 by insulin via a rapamycin‐sensitive signalling pathway.

Redpath, N. T., Foulstone, E. J., & Proud, C. G. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00582.x · Cited by 265

The IκB kinase – a bridge between inflammation and cancer

Karin, M. (2008) · Cell Research · doi:10.1038/cr.2008.30 · Cited by 262

Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.

Geoerger, B., Kerr, K., Tang, C. B., Fung, K., Powell, B., Sutton, L. N., Phillips∥, P. C., & Janss, A. J. (2001) · PubMed · Cited by 261

Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163

Ellard, S. L., Clemons, M. J., Gelmon, K. A., Norris, B. D., Kennecke, H. F., Chia, S., Pritchard, K. I., Eisen, A. F., Vandenberg, T. A., Taylor, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3033 · Cited by 259

Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression.

Dhawan, P., Singh, A. B., Ellis, D. L., & Richmond, A. J. (2002) · PubMed · Cited by 255

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

Liu, T.-J., Koul, D., LaFortune, T. A., Tiao, N., Shen, R., Maira, S.-M., Garcia-Echevrria, C., & Yung, W. K. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0160 · Cited by 254

The Principal Rapamycin-Sensitive p70s6k Phosphorylation Sites, T-229 and T-389, Are Differentially Regulated by Rapamycin-Insensitive Kinase Kinases

Dennis, P. B., Pullen, N., Kozma, S. C., & Thomas, G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.11.6242 · Cited by 253

Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function

Jastrzebski, K., Hannan, K. M., Tchoubrieva, E. B., Hannan, R. D., & Pearson, R. B. (2007) · Growth Factors · doi:10.1080/08977190701779101 · Cited by 240

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Gururangan, S., Friedman, A. H., Herndon, J. E., Marcello, J. E., Norfleet, J. A., McLendon, R. E., Sampson, J. H., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9950-0 · Cited by 235

Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.

Tsao, H., Zhang, X., Fowlkes, K., & Haluska, F. G. (2000) · PubMed · Cited by 234

New insights into PTEN

Tamgüney, T., & Stokoe, D. (2007) · Journal of Cell Science · doi:10.1242/jcs.015230 · Cited by 230

New Strategies in Estrogen Receptor–Positive Breast Cancer

Johnston, S. R. D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1823 · Cited by 230

Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound 26 (PKI-587), a Highly Efficacious Dual Inhibitor

Venkatesan, A. M., Dehnhardt, C. M., Santos, E. D., Chen, Z., dos Santos, O., Ayral‐Kaloustian, S., Khafizova, G., Brooijmans, N., Mallon, R. G., Hollander, I. J., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901830p · Cited by 228

The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma

Zhou, L., Huang, Y., Li, J., & Wang, Z. (2009) · Medical Oncology · doi:10.1007/s12032-009-9201-4 · Cited by 225

A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies

Rizzieri, D. A., Feldman, E. J., DiPersio, J. F., Gabrail, N. Y., Stock, W., STRAIR, R. K., Rivera, V. M., Albitar, M. X., Bedrosian, C. L., & Giles, F. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1372 · Cited by 224

Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer

Sato, T., Nakashima, A., Guo, L., Coffman, K., & Tamanoi, F. (2010) · Oncogene · doi:10.1038/onc.2010.28 · Cited by 223

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

Johnston, P. B., Inwards, D. J., Colgan, J. P., LaPlant, B. R., Kabat, B., Habermann, T. M., Micallef, I. N., Porrata, L. F., Ansell, S. M., Reeder, C. B., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21664 · Cited by 219

The RSK factors of activating the Ras/MAPK signaling cascade

Carriere, A. (2008) · Frontiers in bioscience · doi:10.2741/3003 · Cited by 218

Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin

Huffman, T. A., Mothe‐Satney, I., & Lawrence, J. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022634399 · Cited by 217

The amino acid sensitive TOR pathway from yeast to mammals

Dann, S. G., & Thomas, G. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.04.068 · Cited by 216

Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors

Ballif, B. A., Roux, P. P., Gerber, S. A., MacKeigan, J. P., Blenis, J., & Gygi, S. P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409143102 · Cited by 211

United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling

Manning, B. D., & Cantley, L. C. (2003) · Biochemical Society Transactions · doi:10.1042/bst0310573 · Cited by 211

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy

Morrow, P. K., Wulf, G. M., Ensor, J., Booser, D. J., Moore, J. A., Flores, P. R., Xiong, Y., Zhang, S., Krop, I. E., Winer, E. P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2321 · Cited by 209

Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells.

Grewe, M., Gansauge, F., Schmid, R. M., Adler, G., & Seufferlein, T. T. W. (1999) · PubMed · Cited by 209

Integrin (α6β4) regulation of eIF-4E activity and VEGF translation

Chung, J., Bachelder, R. E., Lipscomb, E. A., Shaw, L. M., & Mercurio, A. M. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200112015 · Cited by 207

Akt3 and Mutant V600EB-Raf Cooperate to Promote Early Melanoma Development

Cheung, M., Sharma, A. K., Madhunapantula, S. V., & Robertson, G. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5867 · Cited by 206

The Mitogen-Activated Protein Kinase Signal-Integrating Kinase Mnk2 Is a Eukaryotic Initiation Factor 4E Kinase with High Levels of Basal Activity in Mammalian Cells

Scheper, G. C., MORRICE, N. A., Kleijn, M., & Proud, C. G. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.3.743-754.2001 · Cited by 202

Therapeutic targets: MTOR and related pathways

Dancey, J. E. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.9.3175 · Cited by 195

Localization of Rheb to the endomembrane is critical for its signaling function

Buerger, C., DeVries, B., & Stambolic, V. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.03.220 · Cited by 192

Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin

Rini, B. I. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4719 · Cited by 183

Mammalian TOR Controls One of Two Kinase Pathways Acting upon nPKCδ and nPKCε*

Parekh, D., Ziegler, W., Yonezawa, K., Hara, K., & Parker, P. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.34758 · Cited by 183

A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)

Kreisl, T. N., Lassman, A. B., Mischel, P. S., Rosen, N. X., Scher, H. I., Teruya‐Feldstein, J., Shaffer, D. R., Lis, E., & Abrey, L. E. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9741-z · Cited by 183

Lost in translation

Bjornsti, M., & Houghton, P. J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.027 · Cited by 180

Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells.

Seufferlein, T., & Rozengurt, E. (1996) · PubMed · Cited by 170

Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors

Steelman, L. S., Navolanic, P. M., Sokolosky, M. L., Taylor, J. R., Lehmann, B. D., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Stadelman, K. M., Terrian, D. M., et al. (2008) · Oncogene · doi:10.1038/onc.2008.49 · Cited by 170

Alterations in VHL as potential biomarkers in renal-cell carcinoma

Gossage, L., & Eisen, T. G. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.42 · Cited by 168

Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma

Patel, P. H., Senico, P., Curiel, R. E., & Motzer, R. J. (2009) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2009.n.004 · Cited by 167

The genome and epigenome of malignant melanoma

Dahl, C., & Guldberg, P. (2007) · Apmis · doi:10.1111/j.1600-0463.2007.apm_855.xml.x · Cited by 165

The Farnesyl Transferase Inhibitor (FTI) SCH66336 (lonafarnib) Inhibits Rheb Farnesylation and mTOR Signaling

Basso, A. D., Mirza, A., Liu, G., Long, B. J., Bishop, W. R., & Kirschmeier, P. T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503763200 · Cited by 162

First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting

Molckovsky, A., & Siu, L. L. (2008) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-1-20 · Cited by 161

Ras caught in another affair: the exchange factors for Ral

Wolthuis, R. M. F., & Bos, J. L. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80016-1 · Cited by 156

The Complexes of Mammalian Target of Rapamycin

Zhou, H., & Huang, S. (2010) · Current Protein and Peptide Science · doi:10.2174/138920310791824093 · Cited by 153

Regulation of Both Glycogen Synthase and PHAS-I by Insulin in Rat Skeletal Muscle Involves Mitogen-activated Protein Kinase-independent and Rapamycin-sensitive Pathways

Azpiazu, I., Saltiel, A. R., DePaoli-Roach, A. A., & Lawrence, J. C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.9.5033 · Cited by 152

Combined Inhibition of MAPK and mTOR Signaling Inhibits Growth, Induces Cell Death, and Abrogates Invasive Growth of Melanoma Cells

Lasithiotakis, K. G., Sinnberg, T. W., Schittek, B., Flaherty, K. T., Kulms, D., Maczey, E., Garbe, C., & Meier, F. E. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.44 · Cited by 152

The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma

Madhunapantula, S. V., & Robertson, G. P. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00585.x · Cited by 148

Elongation Factor-2 Kinase Regulates Autophagy in Human Glioblastoma Cells

Wu, H., Yang, J., Jin, S., Zhang, H., & Hait, W. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1554 · Cited by 146

RAPAMYCIN, A POTENT IMMUNOSUPPRESSIVE DRUG, CAUSES PROGRAMMED CELL DEATH IN B LYMPHOMA CELLS

Muthukkumar, S., Ramesh, T., & Bondada, S. (1995) · Transplantation · doi:10.1097/00007890-199508000-00010 · Cited by 145

Identification of S664 TSC2 Phosphorylation as a Marker for Extracellular Signal-Regulated Kinase–Mediated mTOR Activation in Tuberous Sclerosis and Human Cancer

Ma, L., Teruya‐Feldstein, J., Bonner, P., Bernardi, R., Franz, D. N., Witte, D. P., Cordon‐Cardo, C., & Pandolfi, P. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4798 · Cited by 145

Phosphatidic Acid Regulates Systemic Inflammatory Responses by Modulating the Akt-Mammalian Target of Rapamycin-p70 S6 Kinase 1 Pathway

Lim, H.-K., Choi, Y., Park, W., Lee, T., Ryu, S. H., Kim, S. Y., Kim, J.-R., Kim, J.-H., & Baek, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303789200 · Cited by 142

PPARγ, 10 years later

Lazar, M. A. (2004) · Biochimie · doi:10.1016/j.biochi.2004.10.021 · Cited by 138

Rapamycin inhibits doxorubicin-induced NF-κB/Rel nuclear activity and enhances the apoptosis of melanoma cells

Romano, M. F., Avellino, R., Petrella, A., Bisogni, R., Romano, S., & Venuta, S. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.08.017 · Cited by 138

Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor.

Dilling, M. B., Dias, P., Shapiro, D. N., et al. (1994) · PubMed · Cited by 136

Genome‐wide lethality screen identifies new PI4,5P2 effectors that regulate the actin cytoskeleton

Audhya, A., Loewith, R., Parsons, A. B., Gao, L., Tabuchi, M., Zhou, H., Boone, C. M., Hall, M. N., & Emr, S. D. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600384 · Cited by 136

p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin.

Huang, S., Liu, L. N., Hosoi, H., Dilling, M. B., Shikata, T., & Houghton, P. J. (2001) · PubMed · Cited by 130

High Frequency of Submicroscopic Hemizygous Deletion Is a Major Mechanism of Loss of Expression ofPTENin Uveal Melanoma

Abdel‐Rahman, M. H., Yang, Y., Zhou, X.-P., Craig, E. L., Davidorf, F. H., & Eng, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2418 · Cited by 129

The Pleckstrin Homology Domain Proteins Slm1 and Slm2 Are Required for Actin Cytoskeleton Organization in Yeast and Bind Phosphatidylinositol-4,5-Bisphosphate and TORC2

Fadri‐Moskwik, M., Daquinag, A. C., Wang, S., Xue, T., & Kunz, J. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-07-0564 · Cited by 128

PRAS40 Deregulates Apoptosis in Malignant Melanoma

Madhunapantula, S. V., Sharma, A. K., & Robertson, G. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4234 · Cited by 124

Deregulated Ras signaling in developmental disorders: new tricks for an old dog

Schubbert, S., Bollag, G. E., & Shannon, K. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.004 · Cited by 117

Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease

Panwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D., & Garg, M. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01608-z · Cited by 967

The Roles of Autophagy in Cancer

Yun, C. W., & Lee, S. H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113466 · Cited by 965

Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer

Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773

Rapalogs and mTOR inhibitors as anti-aging therapeutics

Lamming, D. W., Ye, L., Sabatini, D. M., & Baur, J. A. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64099 · Cited by 531

Dysregulation of the IGF‐I/PI3K/AKT/mTOR signaling pathway in autism spectrum disorders

Chen, J., Alberts, I., & Li, X. (2014) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2014.03.006 · Cited by 151

Lysosomal accumulation of mTOR is enhanced by rapamycin

Ohsaki, Y., Suzuki, M., Shinohara, Y., & Fujimoto, T. (2010) · Histochemistry and Cell Biology · doi:10.1007/s00418-010-0759-x · Cited by 22

Author response: Regulation of human mTOR complexes by DEPTOR

Wälchli, M., Berneiser, K., Mangia, F., et al. (2021) · doi:10.7554/elife.70871.sa2

Targeting mTOR globally in cancer: Thinking beyond rapamycin

Shor, B., Gibbons, J. J., Abraham, R. T., & Yu, K. (2009) · Cell Cycle · doi:10.4161/cc.8.23.10070 · Cited by 157

Endosomal docking of mTOR modulates mTORC1 activity

Melone, A. (2014) · edoc (University of Basel) · doi:10.5451/unibas-006266450

mTOR signaling in adipose tissue influences systemic lipid metabolism

Paolella, L. M., Tran, C. M., Chellappa, K., et al. (2018) · The FASEB Journal · doi:10.1096/fasebj.2018.32.1_supplement.536.8